Pfizer's Trispecific Antibody Shows Positive Phase 2 Results in Atopic Dermatitis, Advancing to Phase 3
PFE sits 27% above its 52-week low of $20.915.
Summary
Pfizer announced positive Phase 2 results for its trispecific antibody, Tilrekimig (PF-07275315), in moderate to severe atopic dermatitis. The study met its primary endpoint with statistically significant EASI-75 at week 16 and demonstrated a favorable safety profile. This positive pipeline development is significant for Pfizer, especially following the recent 10-K which detailed asset impairments and upcoming patent cliffs. The success of Tilrekimig, which is also being studied for asthma, strengthens Pfizer's immunology pipeline and offers a potential new revenue stream. Pfizer plans to accelerate Tilrekimig to Phase 3, with a pivotal study expected to start this year, which will be the next major catalyst for the drug.
At the time of this announcement, PFE was trading at $26.65 on NYSE in the Life Sciences sector, with a market capitalization of approximately $153.8B. The 52-week trading range was $20.92 to $27.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.